Drug Patent Watch

JANUARY 5, 2023

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are….

Drugs 52

Drugs Marketing 52

Drug Patent Watch

JANUARY 1, 2023

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are….

Drugs 52

Drugs Marketing 52

Drug Patent Watch

DECEMBER 31, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are….

Drugs 52

Drugs Marketing 52

Drug Patent Watch

JANUARY 4, 2023

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are….

Drugs 40

Drugs Marketing 40

Drug Patent Watch

JANUARY 3, 2023

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are….

Drugs 40

Drugs Marketing 40

Drug Patent Watch

JANUARY 2, 2023

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are….

Drugs 40

Drugs Marketing 40